Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to read an analysis of REGN stock now.

Regeneron Pharmaceuticals (NasdaqGS:REGN) was removed from multiple key indices, a development that may influence its investment appeal and stock liquidity. Over the last month, the company's shares ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

REGN is one of the 7 52-week low dividend stocks to consider Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biotechnology company, develops treatments in ophthalmology, oncology, and immunology.

Regeneron Pharmaceuticals, Inc. (REGN) dividend growth summary: 1 year growth rate (TTM). 3, 5, 10 year growth rate (CAGR) and dividend growth rate.

Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...

Review the current Regeneron Pharmaceuticals Inc (REGN:XNAS) dividend yield and history to decide if REGN is the best investment for you.

Braun Stacey Associates cut its stake in Regeneron Pharmaceuticals by 4.5% during the first quarter, lowering its holdings to ...

The cuts represent less than 4% of the company's global workforce and come on top of about 6,000 roles it eliminated in May. Global vehicle sales fall 13.5% as the electric- vehicle maker struggles to ...